NCT06728410 2026-03-09
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase 2 Recruiting
Clinical Trials
16 trialsNCT07434843 2026-02-27
PEMIGIST
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT06906562 2026-02-17
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT05565794 2025-04-13
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Terminated
NCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06530823 2024-07-31
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Not yet recruiting
NCT04256980 2024-05-30
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT04096417 2024-02-21
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05997459 2023-08-18
A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant
Sun Yat-sen University
Phase 2 Unknown
NCT05216120 2023-07-03
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
Phase 2 Withdrawn
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05651672 2022-12-15
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT05559775 2022-09-29
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05202236 2022-01-21
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown